Clinical trial · Interventional
Value of FLT PET/CT in Radium-223 Therapy of mCRPC Patients
Value of FLT PET/CT in Radium-223 Therapy of Patients With Metastatic Castration-resistant Prostate Cancer
NCT03011749CI-TRIAL-00040545terminatedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of the study is to investigate whether positron emission tomography (PET) using the tracer 18F-Fluorothymidine (FLT) can provide information on proliferative activity in bone marrow of patients receiving Radium 223 therapy and potentially be a predictive marker of hematological toxicity
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Prostate Carcinoma | Prostate Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| FLT PET/CT | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- FLT PET/CT
- description
- FLT PET/CT
- interventionNames
- Other: FLT PET/CT
Primary outcomes (1)
- measure
- Uptake of FLT in hematological bone marrow
- timeFrame
- 3 months
Secondary outcomes (1)
- measure
- Occurrence of hematological toxicity
- timeFrame
- 12 months
Eligibility
Eligibility (as posted)
- Sex
- Male
Show eligibility criteria text
Inclusion Criteria:
* Metastatic castration resistant prostate cancer
* Eligible for Radium-223 therapy
* Informed consent
Exclusion Criteria:
* Inability to understand study protocol
* Extensive metastatic involvement of the axial skeleton ("superscan" on bone scintigraphy)References
Publications (0)
Data not yet available
No reference posted for this study.